<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> reduces the incidence of progression to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in humans with <z:hpo ids='HP_0001513'>obesity</z:hpo> or <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We used an animal model to investigate whether <z:chebi fb="0" ids="6801">metformin</z:chebi> could prevent <z:hpo ids='HP_0011009'>acute</z:hpo> <z:chebi fb="23" ids="18059">lipid</z:chebi>-induced <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and the mechanisms involved </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> or vehicle was administered to rats daily for 1 week </plain></SENT>
<SENT sid="3" pm="."><plain>Rats were studied basally, after 3.75 h of intralipid-<z:chebi fb="5" ids="28304">heparin</z:chebi> or <z:chebi fb="3" ids="17754">glycerol</z:chebi> infusion, or after 5 h of infusion with a hyperinsulinemic-euglycemic clamp between 3 and 5 h </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> had no effect on plasma triacylglycerol or nonesterified fatty acid concentrations and did not alter <z:chebi fb="105" ids="17234">glucose</z:chebi> turnover or gluconeogenic enzyme <z:chebi fb="2" ids="33699">mRNA</z:chebi> after <z:chebi fb="23" ids="18059">lipid</z:chebi> infusion </plain></SENT>
<SENT sid="5" pm="."><plain>However, <z:chebi fb="0" ids="6801">metformin</z:chebi> normalized hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> output and increased liver <z:chebi fb="15" ids="28087">glycogen</z:chebi> during <z:chebi fb="23" ids="18059">lipid</z:chebi> infusion and clamp </plain></SENT>
<SENT sid="6" pm="."><plain>Basal liver (but not muscle or fat) <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase activity was increased by <z:chebi fb="0" ids="6801">metformin</z:chebi> (by 310%; P &lt; 0.01), associated with increased phosphorylation of <z:chebi fb="0" ids="15351">acetyl CoA</z:chebi> carboxylase </plain></SENT>
<SENT sid="7" pm="."><plain>Postclamp liver but not muscle phosphorylated/total Akt protein was increased, whereas basal c-Jun <z:chebi fb="0" ids="29318,29339">NH2</z:chebi>-terminal kinase-1 and -2 protein expression were reduced (by 39 and 53%, respectively; P &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> also increased hepatic basal IkappaBalpha levels (by 260%; P &lt; 0.001) but had no effect on tyrosine phosphorylation or expression of insulin receptor substrate-1 (IRS-1) </plain></SENT>
<SENT sid="9" pm="."><plain>In summary, <z:chebi fb="0" ids="6801">metformin</z:chebi> opposes the development of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:chebi fb="23" ids="18059">lipid</z:chebi>-induced <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in the liver through alterations in multiple signaling pathways </plain></SENT>
</text></document>